Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terbutaline
Drug ID BADD_D02162
Description Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]
Indications and Usage Terbutaline is indicated for prevention and reversal of bronchospasm in patients at least 12 years old, with asthma and reversible bronchospasm associated with bronchitis and emphysema.[L32093,L32098]
Marketing Status approved
ATC Code R03AC03; R03CC03
DrugBank ID DB00871
KEGG ID D08570
MeSH ID D013726
PubChem ID 5403
TTD Drug ID D0M8RC
NDC Product Code Not Available
UNII N8ONU3L3PG
Synonyms Terbutaline | Asthmoprotect | Brethaire | Brethine | Bricanyl | Terbasmin | Bricanyl SA | Butaliret | Butalitab | Contimit | KWD-2019 | KWD 2019 | KWD2019 | Monovent | Taziken | Tedipulmo | Terbul | Terbutalin AL | Terbutalin Stada | terbutalin von ct | Terbutalin-ratiopharm | Terbutalin ratiopharm | Terbutaline Sulfate | Terbuturmant | Arubendol
Chemical Information
Molecular Formula C12H19NO3
CAS Registry Number 23031-25-6
SMILES CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Condition aggravated08.01.03.004--Not Available
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug ineffective08.06.01.006--Not Available
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Fatigue08.01.01.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity vasculitis01.01.04.008; 24.12.04.013; 23.06.02.005; 10.02.02.017--Not Available
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Middle insomnia17.15.03.003; 19.02.01.003--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Rash23.03.13.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene